Issue link: http://osercommunicationsgroup.uberflip.com/i/668581
C h a i n D r u g s t o r e D a i l y 2 7 M o n d a y, A p r i l 1 8 , 2 0 1 6 Our mission is to foster strategic alliances between our customer and our vendor partners, resulting in insight driv- en solutions. CDD: What makes Middlebridge Marketing different? GS: Our passion for excellence and our results. Our business development approach is based on personalized inte- gration of resources. This starts with our sales leadership's strategic engage- ment and encompasses a full comple- ment of sales support services. Every touch point is a valuable component of our go-to-market strategy, including planning, supply chain, analysis, per- sonalization and competitive assess- ment to ensure flawless execution. We work tirelessly to navigate the ever- changing landscape to ensure we are in lockstep with our customer and our manufacturers while bringing forward new ideas and approaches to win at shelf. CDD: What is Middlebridge Marketing's Middlebridge Marketing (C ont'd. from p. 1 ) impact on the development of compre- hensive business plans? DC: It all stems from understanding our customers' needs, and in tandem, the needs of our vendor partners, thus defin- ing the right strategies and executing the tactical elements. It happens because Middlebridge Marketing understands and nurtures each business with great atten- tion to detail. We approach challenges and opportunities with thought-driven solutions. CDD: What is the key to success or longevity, having been in business for 28 years? GS: Partnership and transparency. Delivering value-added services every day. Differentiating ourselves, invest- ing in our business and in our people to deliver best in class results. Most importantly, keeping pace with change. For more information, call 401.728.0040, email dianec@middlebridgemktg.com or gayles@middlebridgemktg.com or go to www.middlebridgemarketing.com. advisors such as Dr. James Andrews and Dr. Gary Meyerson. Our products are dis- tributed through all major and secondary wholesalers and dispensed by major pharmacy partners including Walgreens and CVS Health. CDD: What's the current market for transdermal prescription products? CA: The current United States market for transdermal products is $8.4 billion and growing to over $10 billion in 2017. Oral drug delivery has well docu- mented problems, and transdermal tech- nology provides significant benefit for physicians, patients and payors in effica- cy, safety and value by avoiding costly adverse effects and improving patient adherence. Transdermal technologies provide benefits for systemic drug delivery and local delivery of currently approved products, the latter not being subject to FDA's stringent requirements regarding therapeutic effects. CDD: What are Gensco's currently mar- keted value brands? CA: Gensco's two established legacy brands in the pain market are SpeedGel Rx and LiDORx. In 2015, we launched ColciGel, the first transdermal medica- tion for gout which is a $2.5 billion mar- ket. All of our products are available with our proprietary MDose™, metered dose technology. CDD: What can you tell our readers about your pipeline? CA: Our research and development pipeline for transdermal products is well positioned to extend the life cycle of prod- ucts originally introduced in another form, such as tablets or capsules. Our pipeline in 2016 is extremely strong. Midyear, Gensco will launch an FDA approved Prescription Hydrogel for the treatment of painful wounds, including diabetic skin ulcers, pressure wounds and burns. Our team of scientists are developing a Transdermal Corticosteroid with an expected launch by the end of 2016. Eventually, we will include a few orally administered medica- tions that will be a good adjunct therapeu- tic fit with our products. CDD: What does Gensco provide in the way of patient assistance programs? CA: Copay assistance and cash pay pro- grams are available to all patients through participating pharmacies. As a pharma- ceutical manufacturer, we have a respon- sibility to provide access to safe and effective medications. We recognize the need to assist with the financial burden as our duty. Our corporate focus is to utilize our resources on innovative research and the development of unique delivery sys- tems, and it aligns with our pharmacy partner's efforts to improve access and the quality of life for patients who suffer from pain and debilitating diseases. G ensco P harma (C o nt'd. fro m p. 1 ) CDD: What additional insights do you have about Gensco's value brands? CA: We at Gensco are passionate about continuing to develop partnerships with what we call the 4Ps: Patients, Physicians, Pharmacists and Payors. We are constantly in communication with PBMs and our pharmacy clients to mes- sage healthcare providers and their respective patients on the efficacious benefits as well as the financial value of Gensco products. We expect to continue offering Gensco Brands to the industry which consistently provide efficacy, safe- ty and value. For more information, go to www .genscolabs.com or call 855.743.6726 (7GENSCO). IMMUNOMEDICS DEVELOPS NOVEL ANTIBODY-BASED PRODUCTS FOR AUTOIMMUNE DISEASE AND CANCER THERAPY Immunomedics, Inc. has announced the issuance of U.S. patent no. 9,278,129 for the company's new patent family "Methods of Treating Rapidly Progressive Glomerulonephritis Using Chimeric and Humanized Anti-Histone Antibodies," which will expire in February 2034. This new patent concerns methods of use of the company's proprietary anti- histone antibody. This antibody has potential use in a variety of autoimmune, septic and inflammatory diseases. The issued claims cover use in rapidly pro- gressing glomerulonephritis, a kidney autoimmune disease that is rapidly fatal if left untreated. Histones are important proteins that function as structure components of chromatin. Besides having nuclear func- tions, histones can also be released into circulation by both damaged and activat- ed cells. Recent studies have indicated that circulating histones play a crucial role in sepsis and acute respiratory dis- tress syndrome, thus suggesting that his- tones could serve as promising therapeu- tic targets for infectious and inflammato- ry disorders. Earlier this month, two additional U.S. patents were issued to the compa- ny. Patent no. 9,272,029 relates to the company's new patent family "Interferon-Lambda Antibody Complexes," which was assigned to IBC Pharmaceuticals, Inc., the Company's majority-owned sub- sidiary, and has an expiration date of April 8, 2030. This patent concerns methods and compositions for creating antibody complexes of interferon- lambdas (IFN-λs) using the company's proprietary DOCK-AND-LOCK™ protein conjugation platform technolo- gy. IFN-λs are a group of cytokines that, in animal models, induce both tumor cell death and destruction through innate and adaptive immune responses, suggesting that local deliv- ery of the cytokine might be an adjunc- tive strategy in the treatment of human malignancies. The other patent, 9,272,057, relates to additional claims under the patent fam- ily "Combining Radioimmunotherapy and Antibody-drug Conjugates (ADCs) for Improved Cancer Therapy." This new patent concerns compositions and meth- ods of treating pancreatic cancer using radiolabeled antibodies combined with ADCs. The allowed claims cover saci- tuzumab govitecan (IMMU-132), the company's lead ADC that has been grant- ed Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease, and clivatuzumab tetraxetan, which is being evaluated in a Phase 3 (PANCRIT-1) registration trial as a radiolabeled antibody in patients with advanced pancreatic cancer. "These new patents are the results of our continuing innovative efforts to develop new agents and treatment regi- mens to improve the management of patients with cancer, autoimmune dis- eases and other serious diseases," com- mented Cynthia L. Sullivan, President and Chief Executive Officer. "We believe that they enhance our commercial assets and rich pipeline." For more information, visit www.immunomedics.com.